Flow Depression Headset Now Available by Prescription in US — SkimNews
.jpg)
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Flow Neuroscience received FDA approval last December, and its at-home wearable is now available by prescription in the US, positioned as an alternative to antidepressants taken by roughly one in six American adults.
- The Flow headset is worn on the forehead for 30 minutes daily and delivers low-intensity electrical stimulation to the left frontal lobe—the same brain region targeted by transcranial magnetic stimulation (TMS), a clinic-based treatment that can cost up to $15,000 without insurance and requires five weekly visits for several weeks.
- In a 174-person trial, 45% of participants using Flow's device achieved symptom remission at 10 weeks compared with 22% in a sham-device control group; side effects were limited to mild skin irritation, headaches, and trouble concentrating, contrasting with antidepressants' nausea, weight gain, and sexual problems.
- Flow's US pricing stands at $2,200 for the initial 10-week course and $325 per month afterward, paid entirely out of pocket while CEO Daniel Månsson's company pursues insurance reimbursement.
- Månsson reports more than 65,000 people have used the device in Europe since its 2019 approval, and the UK's National Health Service is currently piloting the headset.
- Early investor Vinod Khosla, the billionaire venture capitalist, argues patients on depression medication would prefer a nondrug option, calling nonchemical treatment the way of the future.
- Flow enters a growing brain-wearable field that includes Cognixion's modified Apple Vision Pro for paralyzed users, Muse's meditation headband, and Elemind's sleep-aid device.
Why it matters: Roughly one in six American adults takes an antidepressant, and Flow's 45% remission rate versus 22% in the sham group gives the device real clinical weight—but at $2,200 upfront plus $325 a month, with no insurance coverage yet, it is far more expensive than generic SSRIs and currently reachable mainly by patients willing and able to pay out of pocket.
Ask SkimNews
